Chloroquine Terminates Stretch-induced Atrial Fibrillation More Effectively Than Flecainide in the Sheep Heart
Overview
Authors
Affiliations
Background: Blockade of inward-rectifier K+ channels by chloroquine terminates reentry in cholinergic atrial fibrillation (AF). However, it is unknown whether inward-rectifier K+ channels and reentry are also important in maintaining stretch-induced AF (SAF). We surmised that reentry underlies SAF, and that abolishing reentry with chloroquine terminates SAF more effectively than traditional Na+-channel blockade by flecainide.
Methods And Results: Thirty Langendorff-perfused sheep hearts were exposed to acute and continuous atrial stretch, and mapped optically and electrically. AF dynamics were studied under control and during perfusion of either chloroquine (4 µmol/L, n=7) or flecainide (2-4 µmol/L, n=5). Chloroquine increased rotor core size and decreased reentry frequency from 10.6±0.7 Hz in control to 6.3±0.7 Hz (P<0.005) just before restoring sinus rhythm (7/7). Flecainide had lesser effects on core size and reentry frequency than chloroquine and did not restore sinus rhythm (0/5). Specific IKr blockade by E-4031 (n=7) did not terminate AF when frequency values were >8 Hz. During pacing (n=11), flecainide reversibly reduced conduction velocity (≈30% at cycle length 300, 250, and 200 ms; P<0.05) to a larger extent than chloroquine (11% to 19%; cycle length, 300, 250, and 200 ms; P<0.05). Significant action potential duration prolongation was demonstrable only for chloroquine at cycle length 300 (12%) and cycle length 250 ms (9%) (P<0.05).
Conclusions: Chloroquine is more effective than flecainide in terminating SAF in isolated sheep hearts by significantly increasing core size and decreasing reentry frequency. Chloroquine's effectiveness may be explained by its inward-rectifier K+ channel blockade profile and suggest that reentry is important to maintain acute SAF.
Exploring Anti-Inflammatory Treatment as Upstream Therapy in the Management of Atrial Fibrillation.
Zheng E, Warchol I, Mejza M, Mozdzan M, Strzeminska M, Bajer A J Clin Med. 2025; 14(3).
PMID: 39941553 PMC: 11818443. DOI: 10.3390/jcm14030882.
Huang J, Wu B, Qin P, Cheng Y, Zhang Z, Chen Y Front Cardiovasc Med. 2023; 10:1270452.
PMID: 38028487 PMC: 10663310. DOI: 10.3389/fcvm.2023.1270452.
Bioengineered peptibodies as blockers of ion channels.
Chidipi B, Chang M, Cui M, Abou-Assali O, Reiser M, Pshenychnyi S Proc Natl Acad Sci U S A. 2022; 119(50):e2212564119.
PMID: 36475947 PMC: 9897444. DOI: 10.1073/pnas.2212564119.
Dasi A, Roy A, Sachetto R, Camps J, Bueno-Orovio A, Rodriguez B Front Physiol. 2022; 13:966046.
PMID: 36187798 PMC: 9522526. DOI: 10.3389/fphys.2022.966046.
Assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine using the CiPA concept.
Thomet U, Amuzescu B, Knott T, Mann S, Mubagwa K, Radu B Eur J Pharmacol. 2021; 913:174632.
PMID: 34785211 PMC: 8590616. DOI: 10.1016/j.ejphar.2021.174632.